(Q27021206)

Bazarbachi A

series ordinal

2

1 reference

language of work or name

1 reference

January 2012

1 reference

1 reference

19

1 reference

issue

1

1 reference

page(s)

68-75

1 reference

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Systematic review of high dose chemotherapy and autologous haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: what is the published evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Hematopoietic cell transplantation for chronic lymphocytic leukemia: an evolving concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Cathepsin-B-dependent apoptosis triggered by antithymocyte globulins: a novel mechanism of T-cell depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Reduced intensity versus full myeloablative stem cell transplant for advanced CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Defining the intensity of conditioning regimens: working definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11q- and 17p-)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900107

10.1177/107327481201900107

21 January 2018

Identifiers

DOI

0 references

PubMed publication ID

22143063

1 reference